Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Palisade Bio in a research note issued to investors on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings per share of ($0.06) for the quarter. The consensus estimate for Palisade Bio's current full-year earnings is ($0.21) per share. Brookline Capital Markets also issued estimates for Palisade Bio's Q2 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at ($0.42) EPS and FY2030 earnings at $0.50 EPS.
A number of other research analysts have also recently issued reports on PALI. Piper Sandler began coverage on Palisade Bio in a report on Monday, December 29th. They issued an "overweight" rating and a $25.00 price target for the company. Clear Str raised Palisade Bio to a "strong-buy" rating in a report on Monday, December 29th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Palisade Bio in a report on Thursday, January 22nd. Stifel Nicolaus began coverage on Palisade Bio in a report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 price target for the company. Finally, Wolfe Research began coverage on Palisade Bio in a report on Thursday, April 9th. They issued an "outperform" rating and a $7.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palisade Bio currently has a consensus rating of "Moderate Buy" and an average target price of $10.20.
Read Our Latest Report on Palisade Bio
Palisade Bio Stock Performance
Shares of NASDAQ PALI opened at $2.50 on Tuesday. The stock has a market cap of $414.70 million, a PE ratio of -1.18 and a beta of 1.36. The business has a fifty day moving average of $1.89 and a two-hundred day moving average of $1.90. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.64.
Institutional Trading of Palisade Bio
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers bought a new stake in Palisade Bio during the 4th quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $28,000. Atom Investors LP acquired a new position in shares of Palisade Bio during the 4th quarter worth about $33,000. Finally, Barclays PLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $35,000. 11.79% of the stock is owned by institutional investors.
Palisade Bio Company Profile
(
Get Free Report)
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Palisade Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.
While Palisade Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
